Results 91 to 100 of about 1,132,527 (387)

Dual‐Functional Polyphosphoesters for Gene Delivery: Synergistic Effects of Guanidinium and Hydrophobic Side Chains in Degradable Polymers

Advanced Healthcare Materials, EarlyView.
This study presents guanidinium‐ and indole‐functionalized polyphosphoesters as degradable, non‐viral gene delivery vectors. Through precise tuning of charge density and hydrophobicity, these polymers form stable polyplexes with low toxicity. Remarkably, minor structural changes yield up to 200‐fold differences in transfection efficiency, highlighting ...
Markus Kötzsche, Andreas Dzierza, Jan Egger, Timo Rheinberger, Christin Weilandt, Frederik R. Wurm, Ivo Nischang, Dagmar Fischer, Kalina Peneva   +8 more
wiley   +1 more source

A multimodal iPSC platform for cystic fibrosis drug testing

Nature Communications, 2022
Hundreds of mutations in the gene CFTR lead to cystic fibrosis and represent a challenge to developing therapeutics. Here, authors demonstrate the ability of airway cells derived from human iPSCs to model genotype-specific CFTR function as well as ...
Andrew Berical, Rhianna E. Lee, Junjie Lu, Mary Lou Beermann, Jake A. Le Suer, Aditya Mithal, Dylan Thomas, Nicole Ranallo, Megan Peasley, Alex Stuffer, Katherine Bukis, Rebecca Seymour, Jan Harrington, Kevin Coote, Hillary Valley, Killian Hurley, Paul McNally, Gustavo Mostoslavsky, John Mahoney, Scott H. Randell, Finn J. Hawkins   +20 more
doaj   +1 more source

Bacteria in the airways of patients with cystic fibrosis are genetically capable of producing VOCs in breath. [PDF]

, 2016
Breath contains hundreds of volatile organic compounds (VOCs), the composition of which is altered in a wide variety of diseases. Bacteria are implicated in the formation of VOCs, but the biochemical mechanisms that lead to the formation of breath VOCs ...
Blake, Donald, Bos, Lieuwe DJ, Meinardi, Simone, Whiteson, Katrine   +3 more
core   +2 more sources

Probiotic‐Based Materials as Living Therapeutics

Advanced Materials, EarlyView.
Recent advances in Engineered Living Materials are highlighted, integrating synthetic biology and advanced materials, with a focus on probiotic‐based therapeutics. Probiotic Living Materials hold great potential for biosensing, infection treatment, osteogenesis, wound healing, vaginal and gastrointestinal disorders, and cancer therapy. breakthroughs in
Laura Sabio, Graham J. Day, Manuel Salmeron‐Sanchez   +2 more
wiley   +1 more source

Relationship between pulmonary exacerbations and daily physical activity in adults with cystic fibrosis [PDF]

, 2015
The aim of this study was to examine the relationship between pulmonary exacerbations and physical activity (PA) in adults with cystic fibrosis (CF)
Banya, Winston, Bilton, Diana, DI PAOLO, Marcello, Hopkinson, Nicholas S, Palange, Paolo, Quattrucci, Serena, Savi, Daniela, Simmonds, Nicholas   +7 more
core   +2 more sources

Lumacaftor/ivacaftor in cystic fibrosis: effects on glucose metabolism and insulin secretion [PDF]

, 2021
Carla Colombo, Andrea Foppiani, Arianna Bisogno, Simone Gambazza, Valeria Daccò, Erica Nazzari, Alessandro Leone, A. Giana, Andrea Mari, Alberto Battezzati   +9 more
openalex   +1 more source

VX‐659–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles

New England Journal of Medicine, 2018
BACKGROUND The next‐generation cystic fibrosis transmembrane conductance regulator (CFTR) corrector VX‐659, in triple combination with tezacaftor and ivacaftor (VX‐659–tezacaftor–ivacaftor), was developed to restore the function of Phe508del CFTR protein
J. Davies, S. Moskowitz, C. Brown, A. Horsley, M. Mall, E. McKone, B. Plant, D. Prais, B. Ramsey, J. Taylor-Cousar, E. Tullis, A. Uluer, C. Mckee, S. Robertson, R. Shilling, C. Simard, F. van Goor, D. Waltz, F. Xuan, T. Young, S. Rowe   +20 more
semanticscholar   +1 more source

Bacteria‐Responsive Nanostructured Drug Delivery Systems for Targeted Antimicrobial Therapy

Advanced Materials, EarlyView.
Bacteria‐responsive nanocarriers are designed to release antimicrobials only in the presence of infection‐specific cues. This selective activation ensures drug release precisely at the site of infection, avoiding premature or indiscriminate release, and enhancing efficacy.
Guillermo Landa, Gracia Mendoza, Silvia Irusta, Manuel Arruebo   +3 more
wiley   +1 more source

The NSAID glafenine rescues class 2 CFTR mutants via cyclooxygenase 2 inhibition of the arachidonic acid pathway

Scientific Reports, 2022
Most cases of cystic fibrosis (CF) are caused by class 2 mutations in the cystic fibrosis transmembrane regulator (CFTR). These proteins preserve some channel function but are retained in the endoplasmic reticulum (ER).
Graeme W. Carlile, Qi Yang, Elizabeth Matthes, Jie Liao, Véronique Birault, Helen F. Sneddon, Darren L. Poole, Callum J. Hall, John W. Hanrahan, David Y. Thomas   +9 more
doaj   +1 more source

First time identification of Pandoraea sputorum from a patient with cystic fibrosis in Argentina: a case report [PDF]

, 2017
Background: Pandoraea species are considered emerging pathogens in the context of cystic fibrosis (CF) and are difficult to identify by conventional biochemical methods. These multidrug resistant bacteria remain poorly understood particularly in terms of
Alvarez, Florencia, Barrias, Carolina, Bettiol, Marisa, Bosch, María Alejandra, Ferreras, Julian Alberto, Frada, Guillermo, Lagares, Antonio, Leguizamon, Lorena Beatriz, Martina, Pablo F., Martínez, Mónica Elisabeth, Prieto, Claudia Inés, Von Specht, Martha Helena   +11 more
core   +2 more sources